Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non ‐small cell lung cancer: Updated follow‐up results from two phase II trials
ConclusionsEndostar delivered by CIV with CCRT may be a better option than IV in terms of potential survival and safety for unresectable stage III NSCLC.Key pointsSignificant findings of the study Endostar delivered by continuous intravenous pumping might achieve more favorable survival over intravenous injection and reduce adverse hematological reactions in patients with unresectable stage III NSCLC treated with Endostar combined with CCRT.What this study adds The administration route of recombinant human endostatin is also one key factor for survival and safety to consider when treating patients with unresectable stage III NSCLC.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Ma Honglian,
Hui Zhouguang,
PENG Fang,
Zhao Lujun,
Li Dongming,
Xu Yujin,
Bao Yong,
Xu Liming,
Zhai Yirui,
Hu Xiao,
Wang Jin,
Kong Yue,
Wang Lvhua,
Chen Ming Tags: ORIGINAL ARTICLE Source Type: research
More News: Cancer | Cancer & Oncology | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Study